One-year reductions in cisplatin-related chronic kidney disease (CKD) in patients with head and neck (HNC) cancer treated with avasopasem manganese: A prespecified analysis from the phase 3 ROMAN trial.

Authors

Bryan G. Allen

The University of Iowa Hospitals & Clinics, Iowa City, IA

Bryan G. Allen , Douglas R. Spitz , Kranti A. Mapuskar , Diana Zepeda-Orozco , Robert Alan Beardsley , Eugene Paul Kennedy , Carryn M. Anderson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Effects of GC4419 (avasopasem manganese) on chronic kidney disease in head and neck cancer patients treated with radiation and cisplatin.

First Author: Emily J. Steinbach

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Results of a randomized, open-label, multicenter trial to assess the safety, dose, and schedule ofRRx-001(001) in reducing incidence, severity and duration of severe oral mucositis (SOM) inpatients receiving concomitant chemoradiation (CRT) for advanced head and neck cancer (HNC).

First Author: Marcelo Raul Bonomi

insert_chart_outlined

Poster

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

Phase 3 KEYNOTE-992 study of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC).

First Author: Shilpa Gupta

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

XRay Vision: A phase 3 study of xevinapant plus radiotherapy (RT) for high-risk, cisplatin-ineligible patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).

First Author: Robert L. Ferris